Immunological aspects of scorpion toxins

Current status and perspectives

Balkiss Bouhaouala-Zahar, Rahma Ben Abderrazek, Issam Hmila, Naima Abidi, Serge Muyldermans, Mohamed El Ayeb

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Significant progress has been made in immunological studies of scorpion toxins and several formats of antibodies directed against scorpion toxins have been reported. Some of these are commonly used in a specific treatment against envenoming; others are primarily used for immuno-biochemical characterizations. The preparation protocol of the antibody or its fragments can be substantially different from one laboratory to another, which complicates a direct comparison of the potency of the antivenom. The use of immune sera, the total immunoglobulin fraction or Fab and Fab'2 fragments as the therapeutic agent is widespread. A number of monoclonal antibodies have also been reported and used for engineering of Fv, ScFv or Fab fragments. Recently, a novel antibody format - known as nanobodies - derived from HCAbs of camelids and selected after phage display shows great potential to provide a more efficient therapy against scorpion envenoming. Subsequent bispecific derivatives have been designed and their pharmacokinetics have been studied. Distinct advantages and disadvantages have been attributed to these equine, murine or camelid antibodies and their derived fragments. Some fragments are easily amenable into next generation therapeutics after proper manufacturing and provide an ensured availability of the product to the medical community. Through examples, we will show how the comparison of the serotherapeutic effectiveness is compromised due to the absence of standardization, on the preparation of immunogens, production processes and / or nature of the products. We will report on recent advances in the field.

Original languageEnglish
Pages (from-to)358-368
Number of pages11
JournalInflammation and Allergy - Drug Targets
Volume10
Issue number5
DOIs
Publication statusPublished - 1 Jan 2011
Externally publishedYes

Fingerprint

Scorpions
Immunoglobulin Fab Fragments
Antibodies
Single-Domain Antibodies
Immunoglobulin Variable Region
Antivenins
Bacteriophages
Horses
Immunoglobulins
Immune Sera
Therapeutics
Pharmacokinetics
Monoclonal Antibodies

Keywords

  • Anti-venom
  • Antibody fragment
  • Fabotherapy
  • Library
  • Nanotherapy
  • Phage display
  • Scorpion toxin
  • Serotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Bouhaouala-Zahar, B., Abderrazek, R. B., Hmila, I., Abidi, N., Muyldermans, S., & El Ayeb, M. (2011). Immunological aspects of scorpion toxins: Current status and perspectives. Inflammation and Allergy - Drug Targets, 10(5), 358-368. https://doi.org/10.2174/187152811797200713

Immunological aspects of scorpion toxins : Current status and perspectives. / Bouhaouala-Zahar, Balkiss; Abderrazek, Rahma Ben; Hmila, Issam; Abidi, Naima; Muyldermans, Serge; El Ayeb, Mohamed.

In: Inflammation and Allergy - Drug Targets, Vol. 10, No. 5, 01.01.2011, p. 358-368.

Research output: Contribution to journalArticle

Bouhaouala-Zahar, B, Abderrazek, RB, Hmila, I, Abidi, N, Muyldermans, S & El Ayeb, M 2011, 'Immunological aspects of scorpion toxins: Current status and perspectives', Inflammation and Allergy - Drug Targets, vol. 10, no. 5, pp. 358-368. https://doi.org/10.2174/187152811797200713
Bouhaouala-Zahar, Balkiss ; Abderrazek, Rahma Ben ; Hmila, Issam ; Abidi, Naima ; Muyldermans, Serge ; El Ayeb, Mohamed. / Immunological aspects of scorpion toxins : Current status and perspectives. In: Inflammation and Allergy - Drug Targets. 2011 ; Vol. 10, No. 5. pp. 358-368.
@article{a151a7f72410457599751bcbc16096b4,
title = "Immunological aspects of scorpion toxins: Current status and perspectives",
abstract = "Significant progress has been made in immunological studies of scorpion toxins and several formats of antibodies directed against scorpion toxins have been reported. Some of these are commonly used in a specific treatment against envenoming; others are primarily used for immuno-biochemical characterizations. The preparation protocol of the antibody or its fragments can be substantially different from one laboratory to another, which complicates a direct comparison of the potency of the antivenom. The use of immune sera, the total immunoglobulin fraction or Fab and Fab'2 fragments as the therapeutic agent is widespread. A number of monoclonal antibodies have also been reported and used for engineering of Fv, ScFv or Fab fragments. Recently, a novel antibody format - known as nanobodies - derived from HCAbs of camelids and selected after phage display shows great potential to provide a more efficient therapy against scorpion envenoming. Subsequent bispecific derivatives have been designed and their pharmacokinetics have been studied. Distinct advantages and disadvantages have been attributed to these equine, murine or camelid antibodies and their derived fragments. Some fragments are easily amenable into next generation therapeutics after proper manufacturing and provide an ensured availability of the product to the medical community. Through examples, we will show how the comparison of the serotherapeutic effectiveness is compromised due to the absence of standardization, on the preparation of immunogens, production processes and / or nature of the products. We will report on recent advances in the field.",
keywords = "Anti-venom, Antibody fragment, Fabotherapy, Library, Nanotherapy, Phage display, Scorpion toxin, Serotherapy",
author = "Balkiss Bouhaouala-Zahar and Abderrazek, {Rahma Ben} and Issam Hmila and Naima Abidi and Serge Muyldermans and {El Ayeb}, Mohamed",
year = "2011",
month = "1",
day = "1",
doi = "10.2174/187152811797200713",
language = "English",
volume = "10",
pages = "358--368",
journal = "Current Drug Targets: Inflammation and Allergy",
issn = "1871-5281",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Immunological aspects of scorpion toxins

T2 - Current status and perspectives

AU - Bouhaouala-Zahar, Balkiss

AU - Abderrazek, Rahma Ben

AU - Hmila, Issam

AU - Abidi, Naima

AU - Muyldermans, Serge

AU - El Ayeb, Mohamed

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Significant progress has been made in immunological studies of scorpion toxins and several formats of antibodies directed against scorpion toxins have been reported. Some of these are commonly used in a specific treatment against envenoming; others are primarily used for immuno-biochemical characterizations. The preparation protocol of the antibody or its fragments can be substantially different from one laboratory to another, which complicates a direct comparison of the potency of the antivenom. The use of immune sera, the total immunoglobulin fraction or Fab and Fab'2 fragments as the therapeutic agent is widespread. A number of monoclonal antibodies have also been reported and used for engineering of Fv, ScFv or Fab fragments. Recently, a novel antibody format - known as nanobodies - derived from HCAbs of camelids and selected after phage display shows great potential to provide a more efficient therapy against scorpion envenoming. Subsequent bispecific derivatives have been designed and their pharmacokinetics have been studied. Distinct advantages and disadvantages have been attributed to these equine, murine or camelid antibodies and their derived fragments. Some fragments are easily amenable into next generation therapeutics after proper manufacturing and provide an ensured availability of the product to the medical community. Through examples, we will show how the comparison of the serotherapeutic effectiveness is compromised due to the absence of standardization, on the preparation of immunogens, production processes and / or nature of the products. We will report on recent advances in the field.

AB - Significant progress has been made in immunological studies of scorpion toxins and several formats of antibodies directed against scorpion toxins have been reported. Some of these are commonly used in a specific treatment against envenoming; others are primarily used for immuno-biochemical characterizations. The preparation protocol of the antibody or its fragments can be substantially different from one laboratory to another, which complicates a direct comparison of the potency of the antivenom. The use of immune sera, the total immunoglobulin fraction or Fab and Fab'2 fragments as the therapeutic agent is widespread. A number of monoclonal antibodies have also been reported and used for engineering of Fv, ScFv or Fab fragments. Recently, a novel antibody format - known as nanobodies - derived from HCAbs of camelids and selected after phage display shows great potential to provide a more efficient therapy against scorpion envenoming. Subsequent bispecific derivatives have been designed and their pharmacokinetics have been studied. Distinct advantages and disadvantages have been attributed to these equine, murine or camelid antibodies and their derived fragments. Some fragments are easily amenable into next generation therapeutics after proper manufacturing and provide an ensured availability of the product to the medical community. Through examples, we will show how the comparison of the serotherapeutic effectiveness is compromised due to the absence of standardization, on the preparation of immunogens, production processes and / or nature of the products. We will report on recent advances in the field.

KW - Anti-venom

KW - Antibody fragment

KW - Fabotherapy

KW - Library

KW - Nanotherapy

KW - Phage display

KW - Scorpion toxin

KW - Serotherapy

UR - http://www.scopus.com/inward/record.url?scp=80052859547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052859547&partnerID=8YFLogxK

U2 - 10.2174/187152811797200713

DO - 10.2174/187152811797200713

M3 - Article

VL - 10

SP - 358

EP - 368

JO - Current Drug Targets: Inflammation and Allergy

JF - Current Drug Targets: Inflammation and Allergy

SN - 1871-5281

IS - 5

ER -